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ABSTRACT
Background:  Most cancers, including breast cancer, have high rates of glucose 
consumption, associated with lactate production, a process referred as “Warburg 
effect”. Acidification of the tumour microenvironment by lactate extrusion, performed 
by lactate transporters (MCTs), is associated with higher cell proliferation, migration, 
invasion, angiogenesis and increased cell survival. Previously, we have described 
MCT1 up-regulation in breast carcinoma samples and demonstrated the importance 
of in vitro MCT inhibition. In this study, we performed siRNA knockdown of MCT1 
and MCT4 in basal-like breast cancer cells in both normoxia and hypoxia conditions 
to validate the potential of lactate transport inhibition in breast cancer treatment.
Results: The effect of MCT knockdown was evaluated on lactate efflux, 
proliferation, cell biomass, migration and invasion and induction of tumour xenografts 
in nude mice. MCT knockdown led to a decrease in in vitro tumour cell aggressiveness, 
with decreased lactate transport, cell proliferation, migration and invasion and, 
importantly, to an inhibition of in vivo tumour formation and growth.
Conclusions: This work supports MCTs as promising targets in cancer therapy, 
demonstrates the contribution of MCTs to cancer cell aggressiveness and, more 
importantly, shows, for the first time, the disruption of in vivo breast tumour growth 
by targeting lactate transport.
BACKGROUND
Breast cancer is the most common cancer among 
women and the second leading cause of cancer-related 
mortality [1]. It is characterized by its clinical and 
molecular heterogeneity, as it is no longer seen as a single 
disease but rather as a multifaceted disease comprising 
distinct biological subtypes: luminal (A and B), HER2/
neu+, normal breast-like, and basal-like [2, 3]. These 
molecular subtypes have important prognostic implications 
and different predictive values, being the basal-like 
subtype the most aggressive and with poorer prognosis, 
with no targeted therapy so far [4, 5]. Treatment of this 
breast cancer subtype with conventional chemotherapeutic 
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agents maintains the risk of breast cancer recurrence 
substantially high, around 30–40% [6], reinforcing the 
urgent need to look for new therapeutic targets.
It is known that most solid tumours, including breast 
cancer, have high rates of glucose consumption associated 
with lactate production, even in the presence of sufficient 
oxygen to sustain oxidative phosphorylation, by a process 
known as “Warburg effect” [7, 8]. The high glycolytic 
rates can provide several advantages to cancer cells, 
namely the acidification of tumour microenvironment 
by lactate extrusion, which is associated with higher 
cell proliferation, migration and invasion, angiogenesis 
and increased cell survival [9, 10]. To maintain the 
glycolytic flux, cancer cells up-regulate several proteins, 
including glycolytic enzymes and pH regulators, such as 
monocarboxylate transporters (MCTs) that will mediate 
the efflux of lactate [11].
The MCT family, Solute Carrier Family 16 (SLC16), 
comprises fourteen related proteins, being MCT1 and 
MCT4 responsible for the efflux of lactate coupled with a 
proton across the plasma membrane [12-15], contributing 
to the acidic tumour environment, which is adverse to 
non-tumour cells. These transporters require a protein 
chaperone, CD147, to be trafficked to plasma membrane 
and perform their activity [16].
The enhanced rates of glycolysis and glucose 
uptake in tumours are maintained by several adaptive 
mechanisms, including adaptation to hypoxia conditions 
[17-19], in which HIF-1α (Hypoxia inducible factor 1-α) 
is a key player by regulating several metabolism related 
proteins like the glucose transporter 1 (GLUT1), carbonic 
anhydrase 9 (CAIX) and MCTs [17, 20, 21]. In breast 
cancer, our group reported an association between MCT1 
and both GLUT1 and CAIX expression, particularly 
in the basal-like subtype [22], which is associated with 
shorter disease-free survival. Also, MCT1 and CD147, 
alone or in co-expression, were also associated with 
estrogen receptor (ER) and progesterone receptor (PR) 
absence, high histological grade and proliferative index 
(Ki67), and presence of basal markers such as cytokeratin 
5, 14 and vimentin [23], supporting the role of MCT1/
CD147 in breast cancer aggressiveness as well as in the 
maintenance of the glycolytic phenotype. Consistently, 
several authors have demonstrated the importance of 
MCT inhibition in cancer, using both in vitro and in vivo 
models [for review see [24]]. Further, Morais-Santos et 
al. characterized the effect of targeting MCTs, especially 
MCT1, in a panel of breast cancer cell lines. Activity 
inhibition of MCTs with different inhibitors (quercetin, 
lonidamine and α-cyano-4-hydroxycinnamic acid (CHC)) 
decreased in vitro breast cancer cell aggressiveness, 
decreasing glucose consumption and lactate production, 
cell viability, proliferation, migration and invasion. Also, 
in Hs578T cells, which express MCT1 but lower MCT4, 
impairment of lactate transport led to increased cell death 
by apoptosis. Specific inhibition of MCT1 by siRNA in 
the same cells corroborated the results obtained by activity 
inhibition [25]. Also, results from the group in lung cancer 
and in glioblastoma models also anticipate the success of 
targeting MCTs [26, 27].
Thus, the promising results that have been emerging 
in the last years point at MCTs as new promising 
anticancer targets, however, more studies are needed 
to validate the potential of lactate transport inhibition 
in breast cancer treatment. In this study, we show that 
MCT1/4 knockdown reduced lactate transport, cell 
aggressiveness in vitro and, more importantly, inhibited 
tumour formation and reduced in vivo tumour growth.
RESULTS
Cancer cell metabolism is remodelled by hypoxia
A panel of three basal-like breast cancer cell lines, 
with different levels of MCT1/4 expression [25], was 
specifically used in this study to assess the importance of 
each MCT isoform in tumour progression.
MCT1, MCT4 and CD147 expression under 
normoxia and hypoxia conditions is shown in Figure 1A. 
In MDA-MB-468 cells, MCT1 and CD147 were found 
in the cytoplasm and plasma membrane, while MCT4 
was found in the cytoplasm, being maintained in hypoxia 
(Figure 1A). MDA-MB-231 cells which do not express 
MCT1 [28], showed MCT4 and CD147 expression at 
both the cytoplasm and plasma membrane in normoxic 
and hypoxic conditions (Figure 1A). In BT20 cells, the 
reinforcement of MCT1 and CD147 plasma membrane 
expression after hypoxia is more evident, while MCT4, 
even after hypoxia, was not detected in this cell line 
(Figure 1A).
By Western blot analysis (Figure 1B), there was 
differential expression of MCTs and CD147 under 
hypoxia. In MDA-MD-468 cells, MCT1, MCT4 and 
CD147 protein expressions increased approximately 2-, 
4- and 5-fold, respectively. Protein expression alteration in 
MDA-MB-231 cells was not so obvious, with only a 1.1- 
and 1.5-fold change in MCT4 and CD147, respectively. 
Finally, BT20 cells presented an increase in MCT1 of 
about 1.8-fold and an increase of CD147 of about 1.6-fold.
The glycolytic metabolism of the human breast 
cancer cell lines under hypoxia was evaluated by glucose 
and lactate quantification in the culture medium. All cell 
lines significantly increased the efflux of lactate, being 
accompanied by a significant increase in glucose uptake 
only in MDA-MB-468 cells (Figure 1C).
Blocking lactate transport decreases the 
metabolic requirements to support cell 
aggressiveness
To better understand the role of each MCT isoform, 
a single transient knockdown for MCT1 (siMCT1), MCT4 
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(siMCT4) or double transient knockdown for MCT1 plus 
MCT4 (siMCT1/4) was performed, under normoxia and 
hypoxia conditions. As seen by Western blot (Figure 2A), 
MCT1 and MCT4 knockdown was almost complete in 
the three cell lines. Additionally, MCT knockdown was 
even more efficient in hypoxia (Supplementary Figure 
S1A). In MDA-MB-231 and BT20 cell lines, which only 
express one MCT isoform, MCT4 and MCT1 knockdown, 
respectively, was able to efficiently decrease the expression 
levels of CD147 (Figure 2A, Supplementary Figure S1A), 
while, in MDA-MB-468 cell line, only MCT1 or MCT1/4 
knockdown was capable to reduce CD147 expression 
(Figure 2A and Supplementary Figure S1A).
In addition, in MDA-MB-468 cells, lactate release 
and cell proliferation were significantly decreased after 
MCT1 and double knockdown, in both normoxia and 
hypoxia, while MCT4 knockdown showed no effect 
(Figure 2B). Regarding MDA-MB-231 cells, MCT4 
knockdown significantly reduced lactate secretion only 
in hypoxia conditions, while cell proliferation was 
significantly decreased under both normoxia and hypoxia 
(Figure 2C). In contrast, in BT20 cells, after MCT1 
knockdown, lactate secretion and cell proliferation were 
only significantly decreased under hypoxic conditions 
(Figure 2D). The influence of MCT knockdown on cell 
biomass was also accessed and the results showed that 
only MCT1 knockdown induced a significant decrease on 
cell biomass, having a more profound effect under hypoxic 
conditions for both MDA-MB-468 and BT20 cells lines 
(around 30 and 40%, respectively) (Figure 2E).
To evaluate if the decrease of lactate-induced 
acidification of the extracellular media influenced other 
tumourigenic features, we also analysed cell migration 
and invasion. Thus, as observed in Figure 3A, the single 
knockdown of MCT1 or MCT4 and the double knockdown 
were able to significantly decrease cell migration in all 
cell lines (Figure 3A and Supplementary Figure S1B), in 
both normoxia and hypoxia. Regarding cell invasion, in 
Figure 1: The metabolic profile of breast cancer cell lines is modulated by hypoxia. A. Immunofluorescence staining of breast 
cancer cell lines for MCT1 (green), MCT4 (green), CD147 (red) and HIF-1α (red) after 24 hours under normoxic (N) and hypoxic (H) 
conditions (magnification, x400; DAPI- blue nuclear staining). B. Western blot analysis of MCT1 (50kDa), MCT4 (52kDa), CD147 (31–65 
kDa) protein expression under normoxic (N) or hypoxic (H) conditions. β-actin was used as loading control. The graphs represent protein 
quantification of each blot, compared with normoxia (dashed line). C. Glucose consumption and extracellular lactate production by breast 
cancer cell lines after 24 hours of normoxic (N) or hypoxic (H) conditions. Results are the mean of at least three independent experiments 
in triplicate ± SEM. *: p < 0.05; **: p < 0.01; ***: p < 0.001 normoxia vs. hypoxia.
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MDA-MB-468 cells, the percentage of invasive cells was 
significantly reduced in normoxia upon MCT1, MCT4 and 
MCT1/4 knockdown, while, in hypoxia, the inhibition of 
invasion caused by MCT knockdown was lost in siMCT1/4 
(Figure 3B and Supplementary Figure S1C). MCT4 
knockdown in MDA-MB-231 cells decreased cell invasion 
more effectively in normoxia, whereas MCT1 knockdown 
in BT20 cells only decreased significantly cell invasion in 
hypoxia (Figure 3B and Supplementary Figure S1C).
MCT1/4 knockdown impairs tumour growth 
in vivo
To test the in vivo role of MCTs during cancer 
initiation, MDA-MB-468, MDA-MB-231 and BT20 cells 
with transient MCT knockdown were injected into the 
mammary fat pad of nude mice and tumour formation and 
growth was monitored. The duration of in vitro silencing 
in cultured cells in normoxic conditions showed that, 
in MDA-MB-468 cells, silencing of MCT1 and MCT4 
was stable up to 10 days (Figure 4A, Supplementary 
Figure S2A). However, CD147 depletion previously 
observed after MCT1 and MCT1/4 silencing (Figure 2A) 
was not maintained after 10 days of silencing (Figure 4A 
and Supplementary Figure S2A). On the other hand, 
in MDA-MB-231 and BT20 cells, MCT4 and MCT1 
knockdown remained at least until 14 days, as well as 
CD147 (Figure 4A). The efficiency of MCT4 knockdown 
in MDA-MB-231 cells and MCT1 knockdown in BT20 
cells is shown in Supplementary Figure S2A. Additionally, 
along 10 days of silencing, there are significant differences 
in cell proliferation for siMDA-MB-231 and siBT20 cells, 
and no difference for siMDA-MB-468 cells, compared to 
controls (Supplementary Figure S2B). The silencing levels 
at the time of injection are shown by Western blot in each 
cell line panel (Figure 4B, 4C and 4D).
In the in vivo model, MCT1 and MCT4 depletion 
resulted in a remarkable reduction of tumour growth for 
Figure 2: MCT knockdown impairs glycolytic metabolism and cell proliferation. A. Western blot results for MCT1, MCT4 
and CD147 in silenced breast cancer cell lines under 24 hours of normoxia (N) or hypoxia (H). β-actin was used as loading control. 
B,C,D. Lactate production by silenced cells in normoxia (N) and hypoxia (H) compared to control (Sc - scramble) and percentage 
of cell proliferation by BrdU incorporation of silenced cells comparing to control (dashed line) in normoxia (N) and hypoxia (H). 
E. Percentage of cell biomass of silenced cells compared to respective control (dashed line). Results are the mean of at least three 
independent experiments in triplicate ± SEM. *: p < 0.05; **: p < 0.01; ***: p < 0.001.
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MDA-MB-231 and BT20 cells (Figure 4C and 4D). In 
particular, in MDA-MB-231 cells, at day 45 after injection, 
tumour volumes were 88 ± 23.4 mm3 in the control group 
versus 20 ± 17.8 mm3 in the MCT4 knockdown group. 
More importantly, in the MCT4 knockdown group, only 3 
out of 8 injected animals developed tumours (Figure 4C). 
In BT20 cells, the depletion of MCT1 was also capable to 
significantly decrease tumour volume from 616 ± 162.4 
mm3 in the control group to 278.8 ± 37 mm3 in the MCT1 
knockdown group (Figure 4D). In this case, all the injected 
animals developed tumours. Finally, in MDA-MB-468 
cells, the single or double MCT knockdown were not 
able to significantly reduce tumour volume or inhibit its 
formation (Figure 4B).
To investigate the effect of MCT knockdown in in 
vivo tumour growth inhibition, tumours were collected 
at the end of the experiment (day 45) and examined by 
immunohistochemistry for the expression of MCT1, 
Figure 3: MCT knockdown decreases in vitro cell migration and invasion. A. Percentage of cell migration after 24 hours 
of normoxia (N) or hypoxia (H). Silenced cells were compared with the respective control (dashed line). Representative pictures of cell 
migration at 0 hours and 24 hours are shown (scale bar 100 μm). B. Percentage of invasive cells after 24 h of normoxia (N) or hypoxia 
(H). Silenced cells were compared with the respective control (Sc - scramble). Representative pictures of cell invasion at 24 hours of 
normoxia (left panel) or hypoxia (right panel) are shown. Results are the mean of at least three independent experiments in triplicate ± 
SEM. *: p < 0.05; **: p < 0.01; ***: p < 0.001.
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MCT4, CD147 and CAIX (Figure 5B, 5C), CD31 and 
Ki67 (Supplementary Figure S2D). H&E staining 
demonstrated that MDA-MB-468 silenced and control 
groups presented high levels of necrosis, when comparing 
to MDA-MB-231 or BT20 tumours (Figure 5A). Also, 
after 45 days, MCTs were re-expressed in cancer cells, 
however, in MDA-MB-468 tumours, the expression of 
MCT1 and CD147 was predominantly at the plasma 
membrane in siMCT1, siMCT4 (Supplementary 
Figure S2C) and siMCT1/4 groups (Figure 5B), while 
for MDA-MB-231 and BT20 tumours, MCT1, MCT4 
and CD147 re-expression was limited to the cytoplasm 
(Figure 5B). MDA-MB-231 and BT20 tumours did not 
express MCT1 and MCT4, respectively (Figure 5B). 
Results also showed that the levels of proliferation 
(Ki67) and vessel density (CD31) were not altered 
between control and knockdown groups (Supplementary 
Figure S2D). Finally, CAIX expression, a cancer cell pH 
regulator, was more evident in MDA-MB-468 scramble 
and knockdown tumour groups (Figure 5B) than in MDA-
MD-231 and BT20 tumours, which expression was in its 
majority in the control groups (Figure 5B) compared to 
the silenced groups.
DISCUSSION
Glycolytic metabolism has recently been 
proposed as a fundamental mechanism in the metabolic 
reprogramming of cancer cells [10]. In fact, the large 
amounts of glucose consumed by tumour cells has been 
useful in the diagnosis of breast cancer using 18FDG PET-
scanning, particularly in the detection of metastases of 
primary tumours, recurrent disease and to monitor therapy 
response [29, 30]. As a consequence, several proteins are 
differentially expressed to sustain the glycolytic phenotype 
of tumour cells, like some pH regulators such as CAIX, 
MCTs and other proteins of the glucose pathway [17, 23]. 
Being basal-like tumours a very aggressive group of breast 
tumours [3, 5], without specific molecular therapy [4] and 
with high MCT1 expression, and very low positivity in 
the normal breast tissue [23], this molecule is seen as a 
promising therapeutic target for this breast cancer subtype.
In this work, we exposed breast cancer cell lines 
to hypoxia to enhance glycolysis and impair oxidative 
phosphorylation, a common feature in tumours with 
disrupted vasculature [8, 31]. Our results show a shift from 
oxidative phosphorylation to a more glycolytic phenotype 
Figure 4: Knockdown of MCT1 and MCT4 decreases tumour volume in vivo. A. Western Blot results showing MCTs 
knockdown after 10 days in MDA-MB-468 cells and 14 days in MDA-MB-231 and BT20 cells. β-actin was used as loading control. B,C,D. 
MCT1, MCT4 and CD147 protein expression evaluated by Western Blot at the time of injection in the mammary fat pad of nude mice of 
the different cell lines. Representative picture of excised tumours after 45 days (middle panel) and the respective tumour volume (mm3) in 
each animal group. The numbers in brackets indicate: number of animals with formed tumours/total number of animals in each group. The 
in vivo experiments were repeated twice. *: p < 0.05 siMCTs groups compared to scramble groups.
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in hypoxia, by increased lactate secretion, particularly in 
MDA-MB-468 and BT20 cells, as well as upregulation 
of the studied proteins, allowing cells to grow under 
intermittent hypoxia [9, 19] reinforcing the importance 
of glycolysis. Consequently, it is expected that hypoxic 
cells would be more dependent on MCT1/4 expression 
to export lactate, avoiding acid-induced necrosis and/or 
apoptosis. Thus, inhibition of MCTs by siRNA would be 
more effective in hypoxic conditions once cancer cells rely 
exclusively on glycolysis.
Our results show that MCT1 knockdown was more 
effective in hypoxia, with a higher decrease in lactate levels, 
cell biomass and cell invasion in BT20 cells. The drastic 
reduction observed in in vivo tumour growth corroborates 
these findings. Another study showed that treatment with 
metformin, which impairs oxidative phosphorylation 
forcing glycolysis, increase the response and the efficacy of 
MCT1 inhibitors [32]. Also, treatment of glycolytic cells, 
without MCT4, with a specific inhibitor of MCT1 showed 
a decrease in intracellular pH resulting in suppression 
Figure 5: MCT knockdown inhibits metabolism-related protein re-expression at the plasma membrane. A. Hematoxylin 
and Eosin staining of representative tumours. B. Immunohistochemical expression of MCT1, MCT4, CD147 and CAIX in the excised 
tumours. C. CAIX, MCT1 and MCT4 expression in siMCT1/MCT4 MDA-MB-468 tumours in peri-necrotic areas. The areas surrounded 
by the yellow line represent necrosis (N).
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of tumour growth [33]. Results from our group also 
demonstrated that in vitro silencing of MCT1 decreased 
lactate efflux, migration and invasion in both glioma and 
breast cancer cells [25, 27], as it happened with MCT 
activity inhibition using classical MCTs inhibitors [25].
Furthermore, silencing of MCT4 in MDA-MB-231 
cells, in which MCT1 is silenced by methylation [28], was 
also able to decrease lactate secretion and proliferation, 
but not cell biomass. However, hypoxic conditions seem 
to have no influence in vitro comparing to normoxia, 
probably because MDA-MB-231 cells present a more 
pronounced glycolytic phenotype, with high glycolytic 
rates even in the presence of oxygen (Warburg effect). 
As expected, migration and invasion were also affected, 
probably due to the interaction between MCT4 and β1-
integrin at the leading edge of migrating cells, as reported 
by others in the same breast cancer cell line [34]. Also, 
the high reduction of tumour volume demonstrates the 
great potential of targeting MCT4 in tumours where 
MCT1 is absent. This was also corroborated by the 
observed inhibition tumour initiation in 5 of 8 animals, 
upon depletion of MCT4. Additionally, ectopic expression 
of MCT4 in transformed fibroblasts (poor tumourigenic 
cells) completely restored tumourigenicity, pointing at 
MCT4 as a pro-tumoural molecule [33].
The combined silencing of MCT1 and MCT4 
in MDA-MB-468 cells was expected to also have 
some effect in tumour reduction since, in vitro, we 
demonstrated a decrease in lactate secretion. However, 
it fails to reduce cell biomass and invasion in hypoxia. 
Moreover, MCT1 knockdown had also no effect in 
reduction of tumour volume in vivo. As MCT4 expression 
was mostly cytoplasmic, the results obtained for MCT4 
knockdown in these cells were expected. As shown in 
previous work [25], this cell line presents lower MCT1 
and MCT4 expression than the other two cell lines, 
which probably means a lower dependence on MCTs 
than MDA-MB-231 and BT20 cells, not showing tumour 
growth inhibition.
Interestingly, contrary to MDA-MB-231 and BT20 
cells, after 10 days of silencing, MDA-MB-468 cells re-
expressed CD147. This protein play an essential role in 
MCT trafficking to the plasma membrane and activity of 
MCT1 and MCT4, but also in the regulation of matrix 
metalloproteinases production [35]. Although other authors 
attributed the major pro-tumoural role of CD147 by 
chaperoning MCTs, other CD147 pro-tumoural roles, like 
interaction with signalling integrins, CD98/LAT1 complex 
and promotion of metalloproteinases were also proposed 
[33]. Once CD147 was re-expressed within a few days after 
MCT knockdown, this protein may induce proteins with 
a pro-tumoural function, like metalloproteinases, failing 
in the reduction of tumour volume even with low MCT 
expression, however more studies are needed to support 
this hypothesis. A particular finding was the high levels 
of necrotic areas in MDA-MB-468 tumours compared to 
the other tumour xenografts. Although several studies have 
reported necrosis as an expected result from MCT inhibition 
[36-38] the marked levels of necrosis in the control group, 
excludes MCT knockdown as the cause for tumour necrosis. 
The proliferation curves along 10 days of silencing show 
that MDA-MB-468 silenced cells proliferate at the same 
rate as control cells, supporting the in vivo results for this 
cell line. Moreover, as re-expression of MCT1 and CD147 
was at the plasma membrane in MDA-MB-468 tumours, 
this will probably prevent the decrease of tumour growth. In 
contrast, in tumours in which MCT expression is restricted 
to one MCT isoform (MDA-MB-231 and BT20 tumours), 
re-expression of MCTs and CD147 after 45 days was 
only cytoplasmic, suggesting a possible disruption in the 
trafficking to the plasma membrane.
CAIX plays a role in the maintenance of intracellular 
pH levels of glycolytic cancer cells [39]. This protein was 
previously associated with MCT1 in a subset of breast 
cancer basal-like tumours and was also correlated with a 
shorter disease-free survival [22], pointing at CAIX as a 
marker of tumour aggressiveness. Also, in another study 
using invasive breast carcinomas, it was shown that 
overexpression of CAIX was correlated with poor prognosis 
[40]. Our present results showed CAIX expression in all 
control groups, probably as an initial response to tumour 
hypoxia, with a particular strong expression in MDA-
MB-468 tumours and, in this case, being also expressed 
in the knockdown groups, probably contributing to the 
aggressive behaviour of tumour. There was a clear CAIX 
staining in the peri-necrotic areas with correspondence to 
either MCT1 or MCT4 positivity, supporting the role of 
CAIX in the maintenance of intracellular pH in glycolytic 
cells expressing MCT1/4. In contrast, in tumours which 
volume was reduced after MCT knockdown, re-expression 
of CAIX was almost insignificant.
Importantly, the increasing interest in metabolic-
related targets, like MCT1, is driving the development 
of new classes of specific and high-affinity inhibitors, 
including the MCT1 specific inhibitors developed 
by AstraZeneca. Currently, a Phase 1 clinical trial 
(NCT01791595) is recruiting patients with prostate 
cancer, gastric cancer or diffuse large B cell lymphoma, 
to evaluate the maximum dose, the potential side effects 
of the drug and the pharmacokinetic profile of AZD3965, 
a specific inhibitor for MCT1/MCT2, demonstrating the 
pharmacological interest in targeting MCTs in cancer 
therapy [41].
MATERIALS AND METHODS
Cell culture
The human breast cancer cell lines MDA-MB-468, 
MDA-MB-231 and BT20 were obtained from ATCC 
or from collections developed at Drs Elena Moisseva 
(Cancer Biomarkers and Prevention Group, Departments 
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of Biochemistry and Cancer Studies, University of 
Leicester, UK), Marc Mareel (Laboratory of Experimental 
Cancerology, Ghent University Hospital, Belgium) 
and Eric Lam (Imperial College School of Medicine, 
Hammersmith Hospital, London, UK).
All cell lines were routinely cultured in 
DMEM containing D-glucose (4,5 g/l), (Invitrogen), 
supplemented with 10% FBS (Invitrogen) and 1% 
penicillin–streptomycin (Invitrogen), in a 37°C 
humidified atmosphere with 5% CO2. For experiments 
cells were cultivated in DMEM without FBS. Hypoxia 
was achieved using a modular incubator chamber (MIC-
101 Billups-Rothenberg Inc.), with an atmosphere of 
95% nitrogen and 5% CO2, for 16 hours before starting 
the experiment, and maintained under hypoxia until the 
end of the experiment. Oxygen levels were monitored 
using an oxygen sensor (PAC 3500, Dräger) and never 
exceeded 1% at the end of the experiment.
RNA interference and transfection
Silencing experiments were performed using 
5 nM of Silencer Select Validated siRNAs from Ambion 
(MCT1 siRNA: s580 and MCT4 siRNA: s17417), as well 
as nontargeting control siRNA (Silencer Select Negative 
Control No.1 siRNA, 4390843, Ambion), using 1 μl/ml 
of Lipofectamine RNAiMAX (13778-075, Invitrogen), 
according to the manufacturer’s instructions. Since total 
silencing was only observed after 4 days, being maintained 
for at least 2 additional days (confirmed by Western Blot), 
cells were plated at day 3 after silencing and, after overnight 
adherence, the experiments begin (t0) 4 days after silencing.
Glucose and lactate measurement
The metabolic behaviour of the cell lines under 
the different treatment conditions was determined by 
analysing the extracellular amounts of glucose and lactate. 
For that, MDA-MB-468 (6,8 × 104 cells/well), MDA-
MB-231 (3 × 104 cells/well) and BT20 (4 × 104 cells/well) 
silenced and control cells were plated in 48-well plates 
and allowed to adhere overnight. Glucose and lactate 
quantifications were performed after 24 hours under 
normoxia or hypoxia conditions. Glucose and lactate were 
quantified using commercial kits (Roche and SpinReact, 
respectively), according to the manufacturer’s instructions, 
as described previously [27]. Results are expressed as total 
μg of three independent experiments.
Immunofluorescence
MDA-MB-468 (9 × 104 cells/well), MDA-MB-231 
(4 × 104 cells/well) and BT20 (6 × 104 cells/well) cells were 
plated on glass cover slips placed into 12-well plates and 
allowed to adhere overnight. Cells were then fixed after 24 
hours under normoxic and hypoxic conditions. Briefly, cells 
were fixed with 4% paraformaldehyde during 15 minutes 
at room temperature and then washed 5 minutes with 
PBS 1x glicine 10 mM. After, cells were permeabilized 
with triton 0.1% diluted in PBS 1x for 4 minutes and 
then washed with PBS 1x (2 x 5 minutes). After blocking 
with bovine serum albumin 5% (BSA, Sigma Aldrich) 
for 30 minutes, cells were incubated with the respective 
primary antibodies: mouse anti-MCT1 (1:200, sc-365501, 
Santa Cruz Biotechnology), rabbit anti-MCT4 (1:500, sc-
50329, Santa Cruz Biotechnology), mouse anti-CD147 
(1:200, sc-71038, Santa Cruz Biotechnology) and mouse 
anti-HIF-1α (1:100, 610958, BD Biosciences) diluted in 
BSA 5%, overnight at room temperature. After washing 
with PBS 1x (2 x 5 minutes), cells were incubated with 
fluorochrome-conjugated anti-rabbit (1:500, A11008-
AlexaFluor 488, Invitrogen Life Technologies) or anti-
mouse (1:250, A11032- AlexaFluor 594, Invitrogen Life 
Technologies) secondary antibodies, diluted in BSA 5%, 
for 1 hour at room temperature. Finally, slides were washed 
with PBS 1x (2 x 5 minutes) and counter-stained with DAPI 
(Fluoroshield F6057, Sigma-Aldrich).
Western blot
Cell lysis, protein sample preparation and Western 
blot were carried out as previously described [27]. Briefly, 
primary antibodies mouse anti-MCT1 (1:500, sc-365501, 
Santa Cruz Biotechnology), rabbit anti-MCT4 (1:500, sc-
50329, Santa Cruz Biotechnology), mouse anti-CD147 
(1:500, sc-71038, Santa Cruz Biotechnology), mouse anti-
HIF-1α (1:500, 610958, BD Biosciences) and goat anti-
actin (1:500, sc-1616, Santa Cruz Biotechnology) were 
used. Membranes were then incubated with the adequate 
secondary antibodies coupled to horseradish peroxidase 
(Santa Cruz Biotechnology) and bound antibodies were 
visualised by chemiluminescence (Supersignal West Femto 
kit, Pierce, Rockford, IL, USA). Protein quantification was 
performed using ImageJ Software (version 1.41).
Cell biomass analysis
MDA-MB-468 (1 × 104 cells/well), MDA-MB-231 
(6 × 103 cells/well) and BT20 (7 × 103 cells/well) silenced 
and control cells were plated in 96-well plates and allowed 
to adhere overnight in complete DMEM medium. The 
effect of MCT knockdown on total biomass, measured by 
the Sulforhodamine B assay (TOX-6, Sigma-Aldrich), was 
evaluated after 24 hours of treatment (under normoxia and 
hypoxia), after a previous 24 hours period of hypoxic growth 
in the case of the hypoxia treatment condition. Viability 
curves were calculated with GraphPad Prism 5 software.
Cell proliferation assay
MDA-MB-468 (1 × 104 cells/well), MDA-MB-231 
(6 × 103 cells/well) and BT20 (7 × 103 cells/well) 
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silenced and control cells were plated in 96-well plates 
and allowed to adhere overnight. Cell proliferation was 
assessed after 24 hours of normoxia and hypoxia. For the 
proliferation curves along 10 days, MDA-MB-468 (1000 
cells/well), MDA-MB-231 (500 cells/well) and BT20 
(500 cells/well) silenced and control cells were plated 
in 96-well plates and allowed to adhere overnight. Cell 
proliferation was assessed after 2, 4, 8 and 10 days. To 
determine the % of proliferation, cells were incubated 
with 20 μM bromodeoxyuridine (BrdU) for 6 hours before 
the end of each time point and BrdU incorporation was 
assessed according to manufacturer’s protocol (BrdU, Cell 
Proliferation ELISA, Roche Diagnostics), as previously 
described [27].
Migration assay
MDA-MB-468 (6 × 105 cells/well), MDA-MB-231 
(2 × 105 cells/well) and BT20 (3 × 105 cells/well) silenced 
and control cells were plated in 96-well plates and allowed 
to adhere overnight. At t0, silenced cell monolayers were 
washed and a “wound” was made by using a plastic pipette 
tip. The ‘‘wounded’’ areas were photographed by phase 
contrast microscopy at 0 and 24 hours. The migration 
distance was measured using the beWound - Cell Migration 
Tool (Version 1.5) (developed by A.H.J. Moreira, S. 
Queirós and J.L. Vilaça, Biomedical Engineering Solutions 
Research Group, Life and Health Sciences Research 
Institute- University of Minho; available at http://www.
besurg.com/sites/default/files/beWoundApp.zip). beWound 
is an image processing tool to automate the measurement 
of cell migration rate in images from Wound-healing 
assay. This tool comprehends a three step approach: a) 
automatic image split into cell and “wounded” areas using 
an approach based on image appearance differences; b) 
extraction of detailed contours between compacted cell 
layer and “wounded” area; and, c) measurement of N user-
defined lines (5 in current experiments), equally-spaced 
across the image and perpendicular to the “wound” main 
axis. This software allows to remove the user-dependency 
during measurements, while easing the analysis of large 
databases of images.
The migration distance relative to the control was 
calculated with the following formula at each time point: 
relative migration distance (%) = 100 (A–B)/a–b, where 
A/a is the width of cell wound before incubation, and B/b 
is the width of cell wound after incubation; A/B refers to 
the treated condition, a/b refers to the control condition.
Invasion assay
Cell invasion assay was performed using 24 well 
BD Biocoat Matrigel Invasion Chambers, according to the 
manufacturer’s instructions (354480, BD Biosciences) and 
as previously described [27]. MDA-MB-468 (4 × 104 cells/
well), MDA-MB-231 (2,5 × 104 cells/well) and BT20 (3 × 104 
cells/well) silenced and control cells were plated into invasion 
chambers for 24 hours either in normoxia or hypoxia. 
Membranes were photographed in a stereomicroscope and 
invading cells were counted using the Image J software 
(version 1.41, NIH). Invasion was calculated as % of cell 
invasion normalised for the control condition.
Mouse tumour models
Tumour induction was performed by orthotopic 
injection of 1 × 106 MDA-MB-468, MDA-MB-231 and 
BT20 cells silenced for MCTs, in the mammary fat pad of 
six to eight week-old female N:NIH(s)II: nu/nu nude mice. 
Tumour growth was monitored weekly using a calliper. At 
the end of the experiment (45 days), mice were sacrificed 
by cervical dislocation and the tumours removed, fixed 
in 10% buffered formalin, embedded in paraffin and 
sectioned for histological and immunohistochemical 
evaluations. Tumour volume was calculated according to 
the formula V= (L x W2)/2 (L= length, W= width). Animal 
experiments were carried out in accordance with the 
European Guidelines for the Care and Use of Laboratory 
Animals, Directive 2010/63/UE and the National 
Regulation published in 2013 (Diário da República, 1.a 
série- N.o 151-7 de agosto de 2013).
Histology and immunohistochemistry
A standard Haematoxylin and Eosin (H&E) staining 
was performed to assess the morphology of tumours. 
Immunohistochemistry was carried out as previously 
described [27]. The following primary antibodies were 
used: mouse anti-MCT1 (1:500, sc-365501, Santa Cruz 
Biotechnology), rabbit anti-MCT4 (1:500, sc-50329, 
Santa Cruz Biotechnology), mouse anti-CD147 (1:400, sc-
71038, Santa Cruz Biotechnology), as previously described 
[25], rabbit anti-CAIX (1:2000, ab15086, Abcam) and 
mouse anti-Ki67 (1:200, AP10243CM, Gennova), during 
2 hours at room temperature, using UltraVision Detection 
System Anti-polyvalent, HRP (Labvision Corporation). 
Goat anti-PECAM (CD31, 1:400, sc-1506, Santa Cruz 
Biotechnology) diluted in PBS, was incubated overnight at 
room temperature, for further incubation with biotinylated 
horse anti-goat (1:500, BA-9500, Vector Laboratories) 
secondary antibody, 1 hour at room temperature. In the 
remaining steps, the R.T.U. Vectastain Elite ABC Kit 
(Vector Laboratories) was used. Antigen retrieval to Ki67 
and CD31 reactions were performed with citrate buffer, in 
the microwave for 15 minutes.
Statistical analysis
Data from at least three independent experiments, 
each one in triplicate, was stored in GraphPad Prism 5 
software. All conditions were examined for statistical 
significance using two-tailed Student’s t-test for mean 
comparison, being the threshold for significance 
p values <0.05.
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CONCLUSIONS
In summary, our results show that depletion of 
MCT1 and MCT4 in breast cancer decrease tumour cell 
aggressiveness in vitro and tumour formation and growth 
in vivo, pointing at MCTs as promising targets for cancer 
therapy. This work reinforces the previous in vitro results 
[25] and, more importantly, demonstrates for the first time 
disruption of in vivo breast tumour growth by targeting 
lactate transporters, emphasizing the importance of MCTs 
in breast tumour initiation and progression.
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